possibly. You’d think they surely get one sale from somewhere in Europe by year end. But...
•••..look at the numbers..company communication to market says 40,000 locally adv pancreatic cancer cases per year in Europe plus UK. (4,500 in UK.)
••That means by end of year there will have been 30,000 new lapc cases in Europe since award of CE mark. Over 3000 in Uk alone.
•• so as far as we know as of today there not one sale from 30,000 cases. Not one sale in uk from potential market 3,000. Not even from doctors and hospitals in London already set up to use device from their experience on Plancko trial?
so interesting question is what’s the real extent of demand for the device? Do u think one sale by year end in Uk really would cut it for major re-rate?
possibly. You’d think they surely get one sale from somewhere in...
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.66M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $24.39K | 5.747M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 43 | 35921563 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 2967733 | 3 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.5¢ | 0.5¢ | 500000 | ||
| Last updated 14.11pm 31/05/2024 ? | |||||
| OSL (ASX) Chart |